Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis
JPA Samijn, PAW Te Boekhorst, T Mondria… - Journal of Neurology …, 2006 - jnnp.bmj.com
… T cell depletion. To minimise the possibility of reinfusing potentially harmful autoreactive T
cells, … In addition, we applied antithymocyte globulin (ATG) for in vivo elimination of residual T …
cells, … In addition, we applied antithymocyte globulin (ATG) for in vivo elimination of residual T …
Evidence for acute neurotoxicity after chemotherapy
… A pioneering Dutch treatment trial showed that chemotherapy aimed at intense T-cell
depletion followed by autologous bone marrow transplantation did not halt clinical progression in …
depletion followed by autologous bone marrow transplantation did not halt clinical progression in …
[HTML][HTML] Timely referral for device-aided therapy in Parkinson's disease. Development of a screening tool
Background Timely referral of Parkinson's disease (PD) patients to specialized centers for
treatment with device-aided therapies (DAT) is suboptimal. Objective To develop a screening …
treatment with device-aided therapies (DAT) is suboptimal. Objective To develop a screening …
A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis
MA Rocca, T Mondria, P Valsasina… - American journal …, 2007 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: In multiple sclerosis (MS), autologous hematopoietic stem
cell transplantation (AHSCT) induces a profound suppression of clinical activity and MR …
cell transplantation (AHSCT) induces a profound suppression of clinical activity and MR …
Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis
T Mondria, CHJ Lamers, PAW Te Boekhorst… - Journal of Neurology …, 2008 - jnnp.bmj.com
Background: Given the presumed key role for autoreactive lymphocytes in multiple sclerosis
(MS), treatment strategies have been developed to ablate lymphocyte activity. Intrathecal …
(MS), treatment strategies have been developed to ablate lymphocyte activity. Intrathecal …
[HTML][HTML] The H3. 3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma
…, I Armandari, SL Meuleman, MT Mondria… - PLoS …, 2021 - journals.plos.org
While comprehensive molecular profiling of histone H3.3 mutant pediatric high-grade glioma
has revealed extensive dysregulation of the chromatin landscape, the exact mechanisms …
has revealed extensive dysregulation of the chromatin landscape, the exact mechanisms …
Impaired facial emotion recognition in relation to social behaviours in de novo Parkinson's disease
…, J Oen, MJ Brinkman, T Mondria… - Journal of …, 2023 - Wiley Online Library
Facial emotion recognition (FER) is a crucial component of social cognition and is essential
in social‐interpersonal behaviour regulation. Although FER impairment is well‐established …
in social‐interpersonal behaviour regulation. Although FER impairment is well‐established …
New device to control combined lingual and palatal myoclonus
T Mondria, HHW de Gier, AJW Boon - Movement disorders, 2007 - Wiley Online Library
Lingual myoclonus is a poorly understood disorder that may occur in isolation or combined
with palatal myoclonus. In this report, we present the case history of a 21‐year‐old patient …
with palatal myoclonus. In this report, we present the case history of a 21‐year‐old patient …
Validation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson's disease (VALIDATE)
…, B van Harten, M van Kesteren, T Mondria… - … & Related Disorders, 2024 - prd-journal.com
Background: Timely identification of patients with Parkinson’s disease (PD) who may be
eligible for device-aided therapy (DAT) is important but challenging for general neurologists. …
eligible for device-aided therapy (DAT) is important but challenging for general neurologists. …
Timely referral for advanced therapy in Parkinson's disease. Development of a screening tool
Objectives To develop a screening tool for timely referral for advanced therapy (AT) in
patients with Parkinson’s disease (PD), and to compare the newly-developed tool with the …
patients with Parkinson’s disease (PD), and to compare the newly-developed tool with the …